TL;DR — Urolithin A is a gut-derived metabolite of pomegranate and walnut ellagitannins that activates mitophagyA specific form of autophagy that selectively removes damaged or dysfunctional mitochondria, replacing them with healthy ones. Full glossary → — the selective clearance of damaged mitochondria. A Phase 2 RCT in adults 65+ confirmed improved muscle strength and reduced fatigue at 1000 mg/day over 4 months. Only 30–40% of adults can produce meaningful urolithin A from diet alone; direct supplementation bypasses that gap.
Overview & mitophagy mechanism
Urolithin A is not consumed directly from food — it's produced when gut bacteria metabolize ellagitannins found in pomegranate, walnuts, and certain berries. Published data suggest only 30–40% of adults carry gut microbiota capable of producing meaningful urolithin A this way, which is the rationale for supplementing the metabolite directly rather than relying on dietary ellagitannin intake.
Primary hallmarks targeted: Mitochondrial dysfunction · Disabled autophagyThe cellular self-cleaning process that breaks down and recycles damaged proteins, organelles, and pathogens. Full glossary → · Cellular senescence
Ryu et al. 2019 (PMID 31230029, Nature Medicine/Cell Metabolism): first human clinical evidence that an oral compound stimulates mitophagy in skeletal muscle, in a study of middle-aged and older adults. A Phase 2 RCT (PMID 35391504, Cell Reports Medicine 2022) in adults ≥65 confirmed 500 mg/day Mitopure improved mitochondrial gene expression, aerobic endurance, and muscle strength versus placebo over 4 months without adverse events.
Phase 2 RCT: muscle strength + fatigue outcomes
| Reported effect | Study | Hallmark link |
|---|---|---|
| Stimulated mitophagy in skeletal muscle | Ryu 2019, first human evidence | Mitochondrial dysfunction |
| Improved mitochondrial gene expression | Phase 2 RCT (2022), adults ≥65 | Mitochondrial dysfunction |
| Improved aerobic endurance | Phase 2 RCT (2022) | Mitochondrial dysfunction |
| Improved muscle strength | Phase 2 RCT (2022) | Disabled autophagy |
| Extended lifespan in C. elegans | PMID 27400265, Nature Medicine 2016 | Cellular senescence (preclinical) |
The Phase 2 RCT ran 4 months at 1000 mg/day in adults 65 and older, with no reported adverse events — this is genuinely one of the stronger human-trial cases among mitochondrial-targeted compounds, not an extrapolation from animal data alone.
Why standardization is the whole point
Urolithin A is the only commercially available mitophagy-specific compound with human trial data behind a standardized form (Mitopure). Because natural gut conversion from pomegranate/walnut intake varies so widely between individuals, a raw pomegranate extract does not reliably deliver the dose used in the trials — the clinical evidence applies to the standardized compound, not to "eat more pomegranate."
Mitopure vs pomegranate extract — why standardization matters
| Study type | Model | Key reported outcome | Tier |
|---|---|---|---|
| Ryu 2019 (PMID 31230029) | Human, middle-aged/older adults | First evidence of stimulated mitophagy in skeletal muscle | A |
| Phase 2 RCT (PMID 35391504) | Human, adults ≥65 | Improved gene expression, endurance, muscle strength vs placebo | A |
| C. elegans lifespan study (PMID 27400265) | Animal | Mitophagy induction, extended lifespan | B (preclinical) |
← Swipe for more columns →
Consensus: Two Tier A human studies now support urolithin A for mitochondrial aging and muscle quality — a genuinely stronger position than most compounds on this list, most of which rely on a single human trial or none at all.
Where urolithin A disappoints
- The effect sizes are real but modest. The trials moved mitochondrial gene expression and endurance measures more than raw strength, and the absolute changes are incremental — not a dramatic, felt transformation. - The benefit concentrates in older, deconditioned adults. A young, fit person is unlikely to notice much; the mitophagy deficit it corrects is an aging phenomenon. - Most of the human evidence comes from the standardized product's maker. The trials are well-run but broad independent replication is still limited, and the compound is expensive for the size of the effect.
What would change this grade. Urolithin A is A for mitochondrial and muscle-quality markers in older adults — not yet for hard functional outcomes like falls or disability. Independent trials showing those endpoints move would strengthen it; it would soften if independent groups reproduce smaller effects than the maker-sponsored trials.
Dosing: 500 vs 1000 mg, AM with food
| Parameter | Recommendation |
|---|---|
| Dose | 500–1000 mg urolithin A (Mitopure-standardized) |
| BioavailabilityHow much of a compound actually reaches your bloodstream and tissues after you take it. Full glossary → | ~45% |
| Timing | AM, with food |
| Trial-matched dose | 1000 mg/day was the dose used in the Phase 2 muscle-strength RCT |
| Duration before reassessing | 4 months, matching the Phase 2 trial window |
Does urolithin A fit your protocol?
Is your primary target mitochondrial/muscle-quality decline, particularly at age 60+?
500–1000 mg AM with food is trial-matched — track muscle function and hs-CRP over 4 months
Consider whether NMN or Ca-AKG (both broader mitochondrial-support compounds) better match your primary hallmark target
Active cancer treatment or immunomodulating therapy — consult a physician before adding any mitophagy-targeting compound
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
Monitoring: muscle function, hs-CRP
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| Grip strength / muscle function test | Improving trend | Baseline, 4 months | No change → verify compliance and standardized-product sourcing |
| hs-CRP | <1.0 mg/L | Baseline, 4 months | Persistently high → review broader inflammation drivers |
| Subjective fatigue | Improving trend | Weekly log | No change at 4 months → reassess whether this is your primary hallmark lever |
← Swipe for more columns →
Safety, red flags, and contraindications
Well-tolerated in trials, but not zero-consultation
- Consult a physician if pregnant or nursing — insufficient safety data in this population.
- Consult a physician during active cancer treatment — mitophagy-pathway effects on treatment response are not characterized.
- Consult a physician if taking immunomodulating therapy — no characterized interaction profile exists.
- Well-tolerated at 500–1000 mg in both human trials, with no reported adverse events.
- Direct urolithin A supplementation bypasses the variable gut-microbiome conversion step — a real advantage in consistency of dosing, not just marketing language.
Who should skip urolithin A
- Young, fit adults expecting a strength boost — the deficit it fixes is age-related; you likely won't feel it. - Active cancer treatment or immunomodulating therapy — mitophagy effects on treatment response aren't characterized; clear it with your physician first. - Anyone on a tight supplement budget — for the modest effect, a Tier-A foundation or exercise buys more; add this later, not first.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| NMN | Urolithin A clears damaged mitochondria via mitophagy; NMN fuels biogenesis of the replacements | NMN module |
| Spermidine | Spermidine drives general autophagy; urolithin A adds mitochondria-specific mitophagy — complementary, not redundant | Spermidine module |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| — | No well-characterized pharmacological antagonists at trial doses | Urolithin A co-stacks cleanly; the real limiter is cost, not interaction |
| Budget spent before the basics | Not a chemical conflict — but paying for a modest mitophagy effect before exercise/sleep/Tier-A foundation is misallocated | Sequence it after the higher-yield levers |
Personal results template
My Urolithin A results log
| Date | Month | Dose | Grip strength | hs-CRP | Fatigue (1–10) | Notes |
|---|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | — | Baseline |
| YYYY-MM-DD | 4 | 500–1000 mg AM | — | — | — | Primary endpoint, matches Phase 2 RCT window |
← Swipe for more columns →
Response criteria (personal, not clinical): - Meaningful: Improving grip strength/muscle function with stable or improving hs-CRP. - No effect: No change in tracked markers at 4 months with confirmed compliance. - Stop and reassess: Any new symptom, particularly if on immunomodulating therapy.
Compare mitochondrial-targeting approaches
Both target mitochondrial aging — but at completely different points in the process. See where each one actually acts.
Urolithin A vs CoQ10References
- Urolithin A Activates Mitophagy in Human Skeletal Muscle — First Clinical Evidence. Cell Metabolism (2019). PMID 31230029
- Urolithin A Phase 2 RCT: Sustained Mitochondrial Improvement and Muscle Strength in Older Adults. Cell Reports Medicine (2022). PMID 35391504
- PMID 27400265
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.